论文部分内容阅读
重要部位血管的血栓形成性闭塞,是心血管疾病主要临床症状的常见触发因素。在80%以上的急性心肌梗塞(AMI)患者,起病后的4小时内可观察到血栓形成所致的冠状动脉闭塞。已确认的治疗血栓形成的方法之一是给予纤溶酶原活化因子,通过它们激活血液的纤溶系统。纤溶系统由未激活的酶原即纤溶酶原构成,它能被各种纤溶酶原活化因子转化为具有活性的丝氨酸蛋白酶,即纤溶酶。这些纤溶酶原活化因子包括链激酶(SK)、单链尿激酸型纤溶酶原活化因子或前尿激酶(scu-PA)、双链尿激酶型纤溶酶原活化因
Thrombotic occlusion of blood vessels at important sites is a common trigger of the major clinical symptoms of cardiovascular disease. In more than 80% of patients with acute myocardial infarction (AMI), coronary occlusion due to thrombosis is observed within 4 hours of onset. One of the approved treatments for thrombosis is the administration of plasminogen activators through which the fibrinolytic system of the blood is activated. The fibrinolytic system consists of an inactive proenzyme, plasminogen, which can be converted to an active serine protease, plasmin, by various plasminogen activators. These plasminogen activators include streptokinase (SK), single-chain urokinase-type plasminogen activator or pro-urokinase (scu-PA), double-chain urokinase-type plasminogen activator